AMENDMENT UNDER 37 CFR 1.115 U.S. SER. NO. 08/238,405

cytoplasmic domain selected from the group consisting of CD3
zeta, CD3 eta, CD3 gamma, CD3 delta, CD3 epsilon and the gamma
chain of the F<sub>c</sub> receptor,

wherein said extracellular domain and cytoplasmic are not naturally joined together, [and said cytoplasmic domain is not naturally joined to an extracellular ligand binding domain,] and when said [amino acid sequence] chimeric protein is expressed as a membrane bound protein in a selected mammalian host cell under conditions suitable for expression, said membrane bound protein initiates signalling is said host cell when said extracellular domain binds to [at least one] said ligand.

Kindly cancel without prejudice claim 58.

Claim 61, line 1, delete "60" and insert --57--.

## REMARKS

- I. A substitute Declaration will be filed shortly.
- II. In the fifth and sixth full paragraphs on page 2 of the Office Action, certain claims of the instant application were rejected provisionally under the judicially-created doctrine of obviousness-type double patenting over co-pending application Serial Nos. 465,652 and 125,038.

Applicants note that should the provisional double patenting rejection be the only rejection pending in a case, the Examiner will issue that case. Applicants will take appropriate steps in the other case.

- 2 -

Sub /